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a b s t r a c t
HSV-2 is the major cause of genital herpes and its infection increases the risk of HIV-1 acquisition and
transmission. HSV-2 glycoprotein B together with glycoproteins D, H and L are indispensable for viral
entry, of which gB, as a class III fusogen, plays an essential role. HSV-2 gB has seven potential N-linked
glycosylation (N-CHO) sites, but their signiﬁcance has yet to be determined. For the ﬁrst time, we
systematically analyzed the contributions of N-linked glycans on gB to cell–cell fusion and viral entry.
Our results demonstrated that, of the seven potential N-CHO sites on gB, mutation at N390, N483 or
N668 decreased cell–cell fusion and viral entry, while mutation at N133 mainly affected protein
expression and the production of infectious virus particles by blocking the transport of gB from the
endoplasmic reticulum to Golgi. Our ﬁndings highlight the signiﬁcance of N-linked glycans on HSV-2 gB
expression and function.
& 2015 Elsevier Inc. All rights reserved.
Introduction
Herpes simplex virus type 2 (HSV-2), a member of the family
Herpesviridae, is a large enveloped double-stranded DNA virus.
HSV-2 mainly infects epithelial cells and causes genital herpes. It
also infects immuocytes and neuronal cells, leading to encephalitis
and disseminated diseases that affect other organ systems. As a
human pathogen with extreme prevalence, HSV-2 can establish a
life-long latent infection in sacral ganglia, resulting in about 16%
human adults living with a HSV-2 latency worldwide (Looker
et al., 2008). Given that the prevalence of HIV-1 and HSV-2 co-
infection and that HSV-2 infection can facilitate HIV-1 acquisition
and accelerate the progress of AIDS, HSV-2 remains a threat to
human health worldwide (Huang et al., 2012a; Martinelli et al.,
2011; Tan et al., 2013; Zhu et al., 2009).
HSV-1/2 is proposed to enter host cells by fusion with plasma
or endosomal membranes depending on the cell types infected
(Heldwein and Krummenacher, 2008). During either entry path-
way, membrane fusion is mediated by four viral glycoproteins
named gB, gD, gH, gL (Muggeridge, 2000; Turner et al., 1998) and a
gD-speciﬁc cellular receptor (HVEM, Nectin-1/Nectin-2 or 3-O
sulfated heparin sulfate) (Campadelli-Fiume et al., 2000). The
current fusion model for HSV-1/2 is generally accepted as follows.
Firstly, binding of gD to one of its receptors on cell surface induces
conformational changes in gD (Krummenacher et al., 2005).
Subsequently, the conformation altered gD sequentially recruits
and binds to gB and gH/gL heterodimer, resulting in the activation
of gH/gL (Atanasiu et al., 2007; Lazear et al., 2008). Meanwhile, gB
brings viral envelope and host cell membrane together by direct
insertion into cell membrane through its internal fusion loops
(Hannah et al., 2009), which further facilitates the interaction
between gB and gH/gL heterodimer (Atanasiu et al., 2010b).
Activated gH/gL heterodimer upregulates the fusogenic activity
of gB, resulting in the execution of fusion between viral envelope
and cell membrane (Atanasiu et al., 2010a).
As a class III fusion glycoprotein with seven potential N-linked
glycosylation sites, HSV-1 and 2 gB cannot only facilitate viral
infection by promoting fusion, but also mediate virus attachment
through interactions with HSPG or DC-SIGN (de Jong et al., 2008;
Herold et al., 1994; Laquerre et al., 1998). For instance, gB has been
reported to play a predominant role in mediating the attachment
of HSV-2 to target cells (Cheshenko and Herold, 2002). Due to
its importance in HSV-1/2 infection, gB has been extensively
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investigated in relation to its roles in viral entry, with particular
focus on the functional regions (Bender et al., 2007; Chowdary and
Heldwein, 2010; Li et al., 2006) and amino acids involved (Arii
et al., 2010b; Connolly and Longnecker, 2012; Fan et al., 2002;
Uchida et al., 2010; Wang et al., 2009). Although HSV-2 gB-speciﬁc
receptor has not been identiﬁed, the involvement of several HSV-1
gB-speciﬁc cellular receptors (PILR-α, MAG and NMHC-IIA) in viral
infection (Arii et al., 2009, 2010a; Satoh et al., 2008; Suenaga et al.,
2010) suggests the existence of HSV-2 putative receptors.
It has been widely reported that removal of certain glycans
from a wide range of viral glycoproteins has severe impacts on the
viruses by altering protein expression or/and biological activities.
For instance, N-linked glycans on the glycoproteins of HIV-1,
inﬂuenza virus, West Nile virus, Ebola virus, respiratory syncytial
virus and Nipah virus, have been shown to be important for the
fusogenicity and infectivity of the viruses (Aguilar et al., 2006;
Fenouillet et al., 1993; Terence et al., 2006; Vigerust and Shepherd,
2007). N-linked glycans on the glycoproteins of West Nile virus
and Dengue virus have been reported to be required for viral
replication (Fan et al., 2014; Shirato et al., 2004). In addition,
envelope associated N-linked glycans also play roles in viral
virulence, antigenicity, immune evasion (Biering et al., 2012;
Binley et al., 2010; Kobayashi and Suzuki, 2012; Vu et al., 2011;
Yuste et al., 2008) and sensitivity to carbohydrate-binding agents
(Balzarini, 2007; Huang et al., 2011). In addition, gB of HSV-1 has
been shown to be barely detectable on the plasma membrane of
infected cells in the presence of a glycosylation inhibitor (Glorioso
et al., 1983). However, more detailed studies on the signiﬁcance of
glycosylation in both HSV-1 and HSV-2 gBs are currently lacking.
In the current study, we systematically investigated the con-
tribution of N-linked glycans to gB expression, cell–cell fusion and
viral entry.
Results
Inﬂuence of N-CHO site mutation on gB expression and
electrophoretic mobility
HSV-2 gB has seven putative N-linked glycosylation sites (Asn-
X-Ser/Thr, of which X represents an amino acid except proline) at
positions N79, N133, N390, N422, N470, N483 and N668 (Fig. 1A).
We constructed Asn-linked carbohydrate (N-CHO site) (Sodora et
al., 1991a) mutants by introducing a conservative ﬁrst-site amino
acid substitution from Asn to Gln, termed N79Q, N133Q, N390Q,
N422Q, N470Q, N483Q and N668Q, respectively. Wild type (WT)
and mutated gB constructs were transfected into CHO cells for
expression. Following gel analyses (Fig. 1B), N-CHO site mutation
had little effect on gB expression, while most of the gB mutants
except N470Q migrated slightly faster than WT gB, indicating that
these mutated gBs were smaller in molecular weight than WT gB.
These results together implied that six out of the seven putative N-
linked glycosylation sites, including N79, N133, N390, N422, N483
and N668, were likely indeed glycosylated in gB, whereas N470
was an exception since N470Q mutation did not change the
molecular weight of gB. It is known that HSV-1 gB has only six
potential N-linked glycosylation sites at the ectodomain. The
corresponding site of 470NAT472 in HSV-1 gB is a non-glyco-
sylation site (NPT) because proline would interrupt the formation
of a turn or a loop conformation or destabilize the conformation
which allows sugars to be added to the asparagine residue within
the N-X-T/S sequence (Bause, 1983). To further analyze the glyco-
sylation state of N470 in HSV-2 gB, two dual site mutants, termed
N422Q/N470Q and N422Q/N483Q, were constructed. As seen in
Fig. 1C, N422Q/N483Q had a slightly greater mobility than N422Q/
N470Q while the later had the same mobility as N422Q, further
suggesting that the N470 in HSV-2 gB is highly unlikely glyco-
sylated.
HSV-1 gB is initially expressed as a 110-kDa high-mannose
precursor followed by rapid maturation to a 120-kDa form (Sommer
and Courtney, 1991). In agreement, we observed two forms of gB in
transfected cells for WT gB and most of the mutants (Fig. 1B). In
contrast, only the premature form of gB was detected in N133Q-
transfected cells (Fig. 1B), suggesting that N133Q were not processed
to the mature form. It has been reported that expression of viral
membrane glycoproteins including HSV-2 gB seems to follow a classic
exocytotic pathway (Doms et al., 1993; Maggioni and Braakman, 2005;
Papworth et al., 1997). Newly synthesized proteins are glycosylated in
the endoplasmic reticulum (ER) with a high mannose core attached to
the asparagine of the conserved motif N-X-S/T and then processed to
the mature form by trimming and remodeling the oligosaccharide
during transit through ER and Golgi (Rosnoblet et al., 2013). N133Q
likely failed to be transported to the Golgi apparatus.
Inﬂuence of N-CHO site mutation on the transport of gB to the Golgi
apparatus and the cell surface
It is known that glycoproteins are matured in the Golgi and
sorted to their ﬁnal destinations in the trans-Golgi network (TGN)
(Roth, 2002). Since N133Q was unlikely to be transported to the
Golgi apparatus, we asked whether N-CHO site mutation affected
the intracellular trafﬁcking of gB. To test this, co-localization of WT
or mutated gB with TGN46, a marker of TGN, was analyzed. When
observed by confocal microscopy, gB was present diffusely in the
cytoplasm and only a fraction of gB co-localized with TGN46 in gB
high-expressing cells, making the gB-TGN46 co-localization less
representative than that in gB low-expressing cells. In addition, we
Fig. 1. Expression and glycosylation analysis of HSV-2 gB glycan mutants.
(A) Schematic of N-linked glycosylation sites on gB. HSV-2 gB is composed of an
ectodomain, a transmembrane domain and a cytoplasmic domain, of which the
ectodomain contains seven potential N-linked glycosylation sites. Asterisks repre-
sent these potential N-linked glycosylation sites on gB. (B and C) Expression of gB
mutants. CHO cells were transfected with plasmids encoding WT gB or mutants.
48 h post-transfection, total expression of gB was analyzed by Western blot using
anti-HSV-2 PAB13979 with actin as a loading control. One representative experi-
ment out of three is shown.
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Fig. 2. Subcellular localization and cell surface expression of gB glycan mutants. (A) HeLa cells were transfected with plasmids encoding WT or mutated gB for 24 h. After
ﬁxation, cells were co-stained with anti-gB (red) antibody and antibody against TGN46 (green) speciﬁcally recognizing TGN. Co-localization of gB and the TGN was analyzed
by confocal microscopy. Representative confocal images from three independent experiments are shown. Scale bars in all panels represent 20 mm. (B, C and D) Cell surface
expression of gB mutants. CHO cells were transfected with plasmids encoding WT or mutated gB (B and C) or 293T cells were transfected with plasmids expressing gD, gH, gL
and WT or mutated gB (D). 24 h post-transfection, cells were ﬁxed with 4% paraformaldehyde and incubated with anti-HSV-2 PAB13979 (CHO) or anti-gB sera (293T) to
detect the cell surface expression of gB. Cells transfected with empty vector were used as the negative control. The expression of gB mutants was normalized to that of WT
gB. Data shown are mean7SD of three independent experiments with each condition performed in triplicate. npr0.05, nnnpr0.001.
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observed that over expression of gB would lead to vacuolation of
cytoplasm and apoptosis of the transfected cells. Therefore, we
analyzed the co-localization of gB with TGN46 in gB low-exp-
ressing cells to better understand the impact of N-CHO site
mutations on gB intracellular trafﬁcking. As shown in Fig. 2A,
WT gB and most of the mutants co-localized with TGN46 in tran-
sfected cells, whereas N133Q had no apparent co-localization with
TGN46. These results indicated that N-CHO site mutation at N133
likely impaired the trafﬁcking of gB from the ER to the Golgi,
consequently preventing the maturation of gB.
Since only fully matured viral membrane glycoproteins are
transported to and displayed on the cell surface, N-CHO site muta-
tion might affected the transport of gB to the cell surface. There-
fore, CELISA was subsequently carried out to assess whether N-
CHO site mutation affected the expression of gB on cell surface. As
shown in Fig. 2B, mutation at N390, N422, N470, N483 or N668
had little impact on the cell surface expression of gB, whereas
N79Q or N133Q mutation reduced the expression of gB to 72% or
21% of WT, respectively. To conﬁrm that the sharp decrease of
cell surface expression of N133Q was glycan speciﬁc rather than
due to amino acid change, we constructed mutants T135A and
T135S by third-site substitution from Thr to Ala or Ser. As shown in
Fig. 2C, cell surface expression of glycan mutant T135A was below
the detection limit, while cell surface expression of glycan-
retained mutant T135S was reduced to about 65% of WT gB. Taken
together, these results indicate that the decreased expression of
N133Q was probably due to the N-CHO site mutation at N133,
although we cannot completely rule out the possibility that amino
acid substitution might also affect its cell surface expression to
some extent. Similar effects of N-CHO site mutation on cell surface
expression of gB were also observed on 293T cells transiently co-
expressing gD, gH and gL (Fig. 2D).
Impact of gB N-CHO site mutation on cell–cell fusion
gB together with gD, gH and gL are indispensable for HSV-2
infection and spread. We assessed the impact of gB N-CHO site mut-
ation on cell–cell fusion using a quantitative fusion assay. As shown
in Fig. 3A, ﬁve glycan mutants including N79Q, N133Q, N390Q,
N483Q and N668Q exhibited decreased fusion activities. The fusion
activities of N390Q, N483Q and N668Q decreased to 40–50% of WT
gB regardless of target cells expressing HVEM or Nectin-1. Fusion
mediated by N79Q or N133Q also decreased, and in particular, N133Q
almost completely lost its fusion activity, which was highly likely due
to the extremely low level of expression on cell surface resulted from
the blockage of its intracellular transport. In contrast, N422Q and
N470Q had little effect on cell–cell fusion. These data together
indicate that N-linked glycans at position N390, N483 and N668
may contribute to cell–cell fusion. To conﬁrm the notion that the
impairments caused by N390Q, N483Q and N668Q were mainly due
to N-CHO site mutation, we constructed mutants by introducing a
third-site substitution from Thr/Ser to Ala or Ser/Thr. The impact of
these mutations on the fusion activity of gB was examined. As shown
in Fig. 3B, mutants T392A and S485A, with similar expression level of
WT gB on cell surface (Fig. S1), had the same effects on cell–cell
fusion as N390Q and N483Q, decreasing the fusion activities to 40–
50% of WT gB. T670A showed a slightly decreased level of cell surface
expression, and a similar fusion activity compared with N668Q.
Compared with the corresponding glycan mutants, the expression
levels and fusion activities of glycan-retained mutants T392S, S485T
and T670S were similar to those of WT gB, except that T392S showed
a slightly decreased cell–cell fusion activity. In general, our results
indicated that N-linked glycans at positions N390, N483 and N668
are necessary for the optimal fusion activity of gB.
Impact of gB N-CHO site mutation on viral entry
Having demonstrated that mutation of certain potential glycosyla-
tion sites on gB reduced cell–cell fusion, we further investigated
whether such impact could be reproduced in HSV-2 entry. HSV-2
and HSV-1 share 82% identity at the amino acid level, and gB is the
most conserved protein in herpesvirus family functioning in a similar
way in both HSV-2 and HSV-1 entry (Akhtar and Shukla, 2009; Shukla
and Spear, 2001). Due to the unavailability of HSV-2 gB null virus, HSV-
1 gB null virus was used instead in the subsequent experiments, and
such alternative strategy has been generally accepted (Li et al., 2006).
To generate complemented viruses, BHK-21 cells transiently expressing
WT or mutated gB were subsequently infected with HSV-1 gB null
virus. The infectivity of complemented progeny viruses was examined
in Vero cells. As shown in Fig. 4A, N390Q, N483Q and N668Q dec-
reased viral entry to 59%, 79% and 44% of WT gB, respectively.
N79Q also demonstrated reduced activity in the viral entry assay, while
N133Q complemented viruses almost lost entry activity because of the
lack of matured gB in transfected cells. In accordance with the results
from fusion assay, N422Q and N470Q did not affect HSV-2 entry.
Similar results were obtained in viral complement assay performed in
HeLa cells (Fig. 4B). In agreement, gB mutants with decreased level of
Fig. 3. Fusion mediated by gB glycan mutants. (A and B) Effector cells (QT6) were
infected with vTF1.1 expressing T7 RNA polymerase followed by transfection with
plasmids encoding gD, gH, gL and WT gB or mutants. Target cells (CHO) were
transfected with the plasmid encoding luciferase under the control of a T7
promoter and the plasmid encoding HVEM or Nectin-1. 24 h post-tranfection,
effector and target cells were mixed and co-cultured at 37 1C for 9 h before
luciferase activity was measured. Data shown are mean7SD of three independent
experiments with each condition performed in triplicate. npr0.05, nnpr0.01.
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cell–cell fusion also had impaired capability in viral entry. Of note, the
impact of N483Q on viral entry was less severe than that on cell–cell
fusion. Unlike fusion assay using only four glycoproteins gD, gH, gL and
gB, the complemented virus infection system involves more viral
components, some of which may assist viral entry and compensate
the impairments caused by gB N-CHO site mutation to some extent. To
exclude such interference, we further adopted a HIV-1 Env-pseudo-
typed virus system to assess the impact of N-CHO site mutation at
N390, N483 or N668 on the fusion between viral envelope and cell
membrane, using pNL4-3 env-/lucþ virus bearing HVEM to infect
293T cells transiently co-expressing gD, gH, gL and WT or mutated gB.
As shown in Fig. 4C, consistent with the ﬁndings in fusion assay, the
three mutants all impaired the capability of gB in mediating viral entry.
We subsequently used the glycan mutants T392A, S485A and
T670A and the glycan-retained mutants T392S, S485T and T670S
to analyze the contribution of N-linked glycans at N390, N483 and
N668 to HSV-2 entry. As shown in Fig. 4D and E, the complemen-
ted virus with T392S, S485T or T670S kept comparable infectivity
with that of WT gB-complemented virus. T392A and S485A had
the same effects on viral entry as N390Q and N483Q, respectively.
Of interest, unlike N668Q, T670A-complemented virus almost lost
the infectivity. It has been reported that a mutation of gB, which
was ﬁve residues away from T670, abolished the fusion activity
and viral infectivity of HSV-2 because of a defect in oligomeriza-
tion (Li et al., 2006). We therefore conducted immunoﬂuorescence
assay to analyze whether T670A could be recognized by DL16, a
oligomer-speciﬁc monoclonal antibody (Bender et al., 2005). As
shown in Fig. 5, compared with WT gB, T670A was stained nor-
mally with gB anti-sera but poorly with DL16, implying that T670A
mutation highly likely affected the oligomerization of gB. In add-
ition, N390Q, N483Q, N668Q and T392S were stained normally
with both gB anti-sera and DL16, indicating that these mutations
Fig. 4. Entry mediated by gB glycan mutants. BHK-21 cells were transfected with plasmids encoding WT gB or mutants, followed by infection with HSV-1 ΔgB Luc/GFP virus
to produce phenotypically complemented viruses. Vero (A and D) and HeLa (B and E) cells pre-seeded in 96-well plates were infected with 50 μl/well of complemented
viruses at 37 1C for 24 h, lysed and luciferase activity was measured. (C) HIV-1 pseudovirus bearing HVEM were obtained by co-transfecting 293T cells with pNL4-3 env-lucþ
and plasmid encoding HVEM. HIV-1 particles were harvested 48 h post-transfection and incubated with 293T cells transiently co-expressing gD, gH, gL and WT gB or
mutants at 37 1C for 24 h. Cells were lysed and luciferase activity was measured. Infection or entry mediated by gB mutants was normalized to that of WT gB. Data shown are
mean7SD of three independent experiments with each condition performed in triplicate. npr0.05, nnpr0.01, nnnpr0.001.
S. Luo et al. / Virology 483 (2015) 72–8276
unlikely affected gB oligomerization. These results informed that
N-CHO site mutation at N390, N483 or N668 decreased viral entry,
reinforcing our conclusion that N-linked glycans at N390, N483
and N668 contribute to the optimal function of gB.
Discussion
The entry of HSV-2 into target cells is a complex process, which
remains to be further elucidated. HSV-2 gB is a glycosylated
protein critical for virus–cell fusion, but little is known regarding
the signiﬁcance of N-linked glycans in the function of gB in
herpesvirus family. In this study, we systematically investigated
the importance of N-linked glycans on gB. Our results have
demonstrated that, of the seven potential N-linked glycosylation
sites on gB, N-CHO site mutation at N133 affect the intracellular
trafﬁcking and protein maturation of gB, while N-linked glycans at
N390, N483 and N668 are necessary for optimal fusion activity of
gB and viral entry.
Previous studies have shown that HSV-1 gB has two forms of
monomer in infected cells due to posttranslational processing
(Sommer and Courtney, 1991). We observed two forms for WT gB
and most of the glycan mutants but only one for glycan mutant at
N133 regardless of the cell types used for gB expression, implying a
defect in the maturation of gB N133Q mutant. By analyzing the co-
localization between gB and a TGN marker, we observed that gB
N133Q mutant did not co-localize with TGN, suggesting that lack of
glycosylation at N133 might affect the intracellular trafﬁcking of gB
by blocking the exit of gB from the ER. Moreover, in accordance with
a previous report that incomplete glycosylation led to the reduction
of gB on the cell membrane (Glorioso et al., 1983), our results
revealed that N-CHO site mutation at N79 or N133 decreased the
expression of gB on cell surface. In particular, the expression of gB
with N-CHO site mutation at N133 decreased to 20% of WT,
resulting in extremely low activities of fusion and viral entry
mediated by gB. It has been reported that single glycan deletion
could cause impairment on protein expression and viral infectivity.
For example, the glycan deletion of inﬂuenza virus HA at N81
reduced the protein expression because of misfolding (Hebert et al.,
1997), while deglycosylation at N284 of SIV gp120 resulted in a lethal
defect in protein processing, consequently rendering the virus non-
infectious (Pikora et al., 2005). In our study, while most of the gB
glycan mutants displayed similar cell surface expression levels to that
of WT, N-CHO site mutation at N133 severely affected the maturation
of gB and its expression on cell surface. It is believed that newly
synthesized proteins including HSV-1/2 gB are processed to the
mature form in Golgi (Doms et al., 1993) and fully matured gB is
subsequently transported to cell surface or accumulated in TGN or
TGN-derived vesicles (Beitia Ortiz de Zarate et al., 2004, 2007; Calistri
et al., 2007) where HSV-1 acquired the second envelope (Sugimoto
et al., 2008; Turcotte et al., 2005; Wisner and Johnson, 2004).
Therefore, N-CHO site mutation at N133 dramatically affected the
production of infectious HSV-2 particles likely by preventing gB from
entering Golgi for protein maturation.
Considering that glycans at N390, N483 and N668 contribute
to gB-mediated membrane fusion, we modeled the locations of
N-linked glycans based on the crystal structure of HSV-1 gB
(Heldwein et al., 2006; Stampfer et al., 2010) because the crystal
Fig. 5. Immunoﬂuorescence analysis of gB glycan mutants. HeLa cells were transfected with plasmids encoding WT or mutated gB for 24 h. After blocking with 3% BSA in PBS
for 30 min at room temperature, the transfected cells were incubated with gB anti-sera or DL16 at 4 1C for 1 h, followed by a ﬁxation with 4% paraformaldehyde. Cells were
subsequently incubated with Cy3-conjugated goat anti-mouse IgG. Fluorescence was examined under confocal microscopy. Representative confocal images from three
independent experiments are shown. Scale bars in all panels represent 21 mm.
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structure of HSV-2 gB has not been solved (Fig. 6). According to the
crystal structure of HSV-1 gB, the glycosylation motif 390NLT392 is
located in the domain II. It was reported that insertion of two
additional amino acids in the position between residues 395 and 396
of HSV-2 gB abolished cell–cell fusion and viral entry (Li et al., 2006),
suggesting the importance of this region in domain II for gB function.
The domain II of HSV-1 gB contains a functional region important for
the interaction between gB and gH as well as for cell–cell fusion
(Atanasiu et al., 2010b; Bender et al., 2007). However, conformation
independent neutralizing antibody targeting residues 391 to 410 of
HSV-1 gB (corresponding to residues 382 to 402 of HSV-2 gB) only
moderately decreased the fusion activity of gB (Atanasiu et al.,
2010b), implying that these residues may not directly interact with
gH but are possibly to be involved in the formation of a conformation
for gB–gH interaction. In agreement, we found that N-CHO site
mutation at N390 moderately impaired cell–cell fusion. Blocking
glycosylation at N390 possibly impaired the function of gB in fusion
by weakening the interaction between gB and gH/gL. It is known that
glycosylation plays important roles in maintaining the structure of
viral glycoproteins. For instance, N-glycans on HSV-1 gD have been
reported to be important for maintaining the proper structure of gD
protein (Sodora et al., 1991a; Sodora et al., 1991b). In addition,
removal of N-glycans on the variable region 1 of HIV-1 impacted
gp120-gp41 interaction by allosterically modulating the distal gp120-
gp41 association site (Drummer et al., 2013). In addition, removal of
N-glycans proximal to the CD4 binding region of HIV-1 gp120
affected its steric conﬁguration and consequently impaired viral
infectivity (Huang et al., 2012b). Moreover, oligosaccharides adjacent
to the receptor binding site of inﬂuenza virus HA has also been
shown to affect the afﬁnity of HA to neuraminic acid-containing
receptors (Ohuchi et al., 1997a). The motif 668NIT670, belonging to
domain V, is located in the C-terminal arm of gB trimeric coil-arm
complex, which is arranged in an anti-parallel manner and resembles
the six-helix bundles of class I fusogen, thought to provide a driving
force for its refolding from a pre-fusion to a post-fusion conformation
(Melikyan et al., 2000; Russell et al., 2001). In this regard, three arm
amino acids of HSV-1 gB, including I671, H681 and F683, have been
reported to be critical for maintaining the coil-arm trimer in an anti-
parallel manner (Connolly and Longnecker, 2012). Oligosaccharides
in the stem region of inﬂuenza virus HA were reported to maintain
HA in a metastable form required for fusion activity (Ohuchi et al.,
1997b). Similarly, N-CHO site mutation at N668 of HSV-2 gB might
destabilize the post-fusion conformation of the coil-arm trimer or
weaken the interaction between residues in the coil and the arm,
consequently reducing the activity of fusion. Unlike N390 and N668,
the motif 483NAS485 is located in a linker between domain II and
domain III, not included in the crystal structure of HSV-1 gB.
Insertion of ﬁve additional amino acids in this linker region of
HSV-1 gB did not affect its cell surface expression but resulted in
decreased activity in cell–cell fusion and viral entry (Lin and Spear,
2007), implying the importance of this region on the function of gB.
In our study, data from both cell–cell fusion system and HIV-1
Env-pseudotyped virus system indicate that glycans at N390, N483
and N668 are involved in the process of cell/virus–cell fusion. In
agreement, N-CHO site mutation at N390, N483 or N668 was
demonstrated to impair the entry efﬁciency of the complemented
progeny viruses, although the impact of N-CHO site mutation at
N483 on viral entry was less apparent than that in cell–cell fusion.
It is likely that other HSV-1/2 components, which are dispensable
but involved in the process of HSV-1/2 infection, may partially
compensate the impairment of virus–cell fusion caused by gB N-
CHO site mutation. For instance, gC has been shown to share the
same capability as gB in viral absorption (Laquerre et al., 1998). In
addition, HSV-1 gK, UL20, gM, gH, gB and PILRα can assemble a
complex to regulate virus–cell fusion (Chouljenko et al., 2009,
2010; Chowdhury et al., 2013; Kim et al., 2013). The glycoproteins
dispensable for membrane fusion might enhance fusion efﬁciency
by strengthening or stabilizing the association of the fusion core
machinery or by interacting with gB directly to modulate its fusion
activity. Of note, N-CHO site mutation at N668 modestly decreased
vial entry whereas its counterpart T670A completely abolished
viral entry. A mutation, only ﬁve amino acids away from T670, was
reported to abolish cell–cell fusion and viral entry by negatively
affecting the oligomerization of gB (Li et al., 2006), indicating that
this region might be involved in oligomerization. In our study, the
ﬂuorescence intensity of T670A stained with the oligomer-speciﬁc
monoclonal antibody DL16 was apparently lower than that of WT
gB or N668Q, implying that substitution of T670 with an alanine
likely affected the oligomerization of gB or destabilized the gB
trimer in addition to affecting the glycosylation at 668NIT670.
Unexpectedly, mutant T392S demonstrated a negative impact on
gB function. One possible explanation is that the substitution of
Thr with Ser might decrease the glycosylation efﬁciency since pre-
vious studies by others have reported that the Asn-X-Thr sequon
was glycosylated 2–3 fold more than the Asn-X-Ser sequon (Bause
and Legler, 1981; Kasturi et al., 1995). Nevertheless, we cannot rule
out the possibility that this region is sensitive to amino acid
substitutions.
In conclusion, we have demonstrated for the ﬁrst time that, of
the seven potential N-linked glycans on gB, N79 and N133 are
critical for protein expression on the cell surface, of which N133
was essential for intracellular trafﬁcking of gB from ER to TGN,
while N390, N483 and N668 are involved in cell–cell fusion and
viral entry. Taken together, our results highlight the contribution
of N-linked glycans to gB expression and function.
Materials and methods
Cells, viruses, plasmids and antibodies
QT6, Vero, VgB (Vero cells stably expressing HSV-1 gB), HeLa,
BHK-21, 293T and CHO cells were grown in DMEM supplemented
with 10% fetal bovine serum (FBS). The VgB cell line was a gift from
Professors Patricia Spear and Richard Longnecke, and used to
propagate the HSV-1 gB null virus. Genes encoding gB, gD, gH
and gL were ampliﬁed from HSV-2 strain G obtained from LGC
Standards. gB sequence was deposited in the GenBank database
Fig. 6. The location of potential N-linked glycosylation sites on gB. The three
dimensional structure of HSV-1 gB (PDB ID: 2GUM) was generated by using PyMOL
and labeled with different colors to distinguish the functional domains. Positions of
N133, N390, N422 and N668 are shown in the context of the crystal structure of gB.
N390 and N422 (green) lie in domain II in which the binding site of the gH/gL
heterodimer is located, while N668 (red) lies in the C-terminal arm of domain V
which packs against the coils of domain III (yellow) to form a coil-arm trimer. N133
(purple) is located at the linker segment between domain II and domain III.
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(accession no. KP143740). Genes encoding Nectin-1 and HVEM
were ampliﬁed from the cDNAs of HeLa and human PBMCs,
respectively. Ampliﬁed genes were cloned into pcDNA3.1(þ)
(Invitrogen). gB mutants were generated by site-directed muta-
genesis and all programmed mutations were conﬁrmed by DNA
sequencing. pHSV-1F BAC Luc/GFP (Li et al., 2011) was used as a
template to construct pHSV-1F BAC ΔgB Luc/GFP through homo-
logous recombination. Recombinant vaccinia virus vTF1.1 expres-
sing T7 RNA polymerase was previously described (Hu et al.,
2000).
Polyclonal antibody against HSV-2 strain G (PAB13979) was
from Abnova. Mouse monoclonal antibody against HSV-1/2 gB
(ab6506) and Alexa Fluor 488-conjugated donkey anti-sheep IgG
were from Abcam. Sheep polyclonal antibody against TGN46 was
from AbD Serotec. Mouse monoclonal antibody against actin and
HRP-conjugated mouse anti-goat IgG were from Santa Cruz. HRP-
conjugated goat anti-mouse IgG and Cy3-conjugated goat anti-
mouse IgG were from Boster. Alexa Fluor 555-conjugated donkey
anti-mouse IgG was from Beyotime. Anti-gB sera were prepared by
immunizing mice three times with 50 mg gB expressing plasmid
DNA at two-week intervals according to a previous report (Kuklin
et al., 1997). DL16, a gB oligomer-speciﬁc monoclonal antibody,
was kindly provided by Professors Gary H Cohen and Roselyn J
Eisenberg.
Construction of pHSV-1F BAC ΔgB Luc/GFP and preparation of HSV-1
gB null virus
To obtain HSV-1 gB null virus, gB encoding gene was knocked
out from the HSV-1 genome constructed previously (Li et al., 2011;
Sharan et al., 2009). In brief, pHSV-1F BAC Luc/GFP was ﬁrst
introduced into E.coli GS1783 (kindly provided by Dr. Klaus
Osterrieder) by electroporation (2.5 kV, 25 mF capacitance and
200Ω resistance). The E.coli culture was incubated at 42 1C for
15 min to activate the λ red recombinant system carried in E.coli
GS1783, and thereafter, a linear DNA encoding Kanr expression
cassette with a 40 bp homology at each end to that of ul27 was
introduced to completely substitute the target gene through the
activated λ red recombinant system. Recombinant clones were
subsequently screened by growing on LB plates containing kanna-
mycin (30 mg/ml) and veriﬁed by PCR and sequencing. The ul27
knockout BAC DNA was transfected into VgB cells by electropora-
tion (220 V and 950 mF capacitance) to propagate HSV-1 ΔgB Luc/
GFP virus. After plaque formation on VgB cells, the plaque was
collected to produce virus stocks.
Western blot
CHO cells pre-seeded in 6-well plates were transfected with
4 mg plasmid encoding WT or mutated gB or pcDNA3.1(þ) using
Lipofetamine 2000 (Invetrogen). 48 h post-transfection, cells were
harvested and lysed with lysis buffer in the presence of protease
inhibitor cocktail (Roche). Debris and nuclei were removed by
centrifugation. Protein samples were resolved by 6% SDS-PAGE and
transferred onto PVDF membrane using the Bio-Rad Microassay
System. The PVDF membrane was blocked with TBS-T plus 5% non-
fat milk for 2 h followed by incubation with HSV-2 polyclonal
antibody PAB13979 at a dilution of 1:5000 for 2 h at room
temperature. After three washes with TBS-T, the membrane was
incubated with HRP-conjugated mouse anti-goat IgG at a dilution
of 1:8000 for another 1 h at room temperature. Following ﬁve
washes, immunoreactive bands were visualized after development
using ECL chemiluminescent substrate (Beyotime).
Immunoﬂuorescence and confocal microscopy
HeLa cells seeded on 35 mm glass bottom culture dishes were
transfected with 1 mg plasmids encoding gB WT or mutants per
well using Lipofectamine 2000 (Invitrogen) and cultured for 24 h
at 37 1C. Transfected cells were ﬁxed in 4% paraformaldehyde and
permeabilized with 0.2% Triton X-100 in PBS both for 15 min at
room temperature. Following three washes with PBS, cells were
blocked with 3% BSA in PBS for 1 h at room temperature and then
incubated with mouse monoclonal antibody against HSV-1/2 gB
(ab6506) at a dilution of 1:100 for 1 h at room temperature. After
three washes, cells were incubated with Alexa Fluor 555-conj-
ugated donkey anti-mouse IgG at a dilution of 1:500 for 1 h at
room temperature. For Golgi organelle labeling, TGN was stained
with sheep polyclonal antibody against TGN46 at a dilution of
1:250. Thereafter, the cells were incubated with Alexa Fluor 488-
conjugated donkey anti-sheep IgG at a dilution of 1:200. Cell
nuclei were stained with DAPI. After extensive washes, stained
cells were analyzed under Nikon A1 MP confocal microscope
equipped with a 100 oil immersion objective. Image sequences
were processed and analyzed using NIS-elements Viewer software
(Nikon).
Immunoﬂuorescence of cell surface staining
Labeling conditions were similar to those used in immunoﬂuor-
escence and confocal microscopy assay, except that the transfected
cells were ﬁrst blocked with 3% BSA in PBS for 30 min at room
temperature and then incubated with antibodies against gB for 1 h at
4 1C, followed by a ﬁxation with 4% paraformaldehyde in PBS for
10 min at room temperature. After ﬁxation, cells were incubated with
Cy3-conjugated goat against mouse secondary antibody for 1 h at
room temperature. Cell nuclei were stained with DAPI. Stained cells
were analyzed under confocal microscope (UltraView VoX; Perkin-
Elmer Life and Analytical Sciences) equipped with a 60 oil
immersion objective. Image sequences were processed and analyzed
using Volocity software (Perkin-Elmer).
CELISA
The assay was performed as previously described with some
modiﬁcations (Manoj et al., 2004). Brieﬂy, CHO cells growing in 96-
well plates were ﬁrst transfected with 0.2 mg plasmids of gB, gB
mutant or pcDNA3.1(þ) per well using Lipofectamine 2000 (Invitro-
gen) and cultured for 24 h at 37 1C. Cells in plates were ﬁxed in 4%
paraformaldehyde for 15 min. After three rinses with PBS, cells were
incubated with HSV-2 polyclonal antibody PAB13979 for 1 h followed
by incubation with HRP-conjugated mouse anti-goat secondary
antibody for 1 h at room temperature (both 1:5000 diluted in 3%
BSA). Cells were extensively rinsed and the color reaction was
developed using the TMB liquid substrate system for ELISA (Sigma)
and stopped by the addition of 2 N H2SO4. The OD values were
subsequently read in an ELISA plate reader (Tecan) using a test
wavelength of 450 nm and a reference wavelength of 570 nm.
For CELISA, 293T cells pre-seeded in 96-well plates were trans-
fected with plasmids encoding gD, gH, gL and WT gB or gB mutants
or empty vector (40 ng, 40 ng, 40 ng, and 80 ng, respectively) for
24 h. Cells were ﬁxed in 4% paraformaldehyde and incubated with
anti-gB sera (1:500 diluted in 3% BSA), followed by incubation with
HRP-conjugated goat anti-mouse IgG (1:5000 diluted in 3% BSA) at
room temperature. Subsequently, the color reaction was developed
and OD values were read as described above.
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Quantitative fusion assay
Quantitative fusion assay was conducted as previously
described with some modiﬁcations (Hu et al., 2000; Manoj et al.,
2004). Brieﬂy, effector QT6 cells pre-seeded in 96-well plates were
ﬁrst infected with vTF1.1 (MOI¼3) for 1 h at 37 1C followed by
transfection with plasmids encoding gD, gH, gL and gB or a gB
mutant or pcDNA3.1(þ) (20 ng, 20 ng, 20 ng, and 40 ng, respec-
tively). Target CHO cells pre-seeded in 6-well plates were trans-
fected with plasmids expressing HVEM or Nectin-1 and a T7
promoter-controlled reporter gene luciferase (1 mg, 1 mg and 3 mg,
respectively). 4 h post-transfection, the culture for QT6 was
changed to growth medium containing rifampicin (100 μg/ml)
while the culture for CHO was changed to growth medium. After
overnight incubation, target cells were resuspended by trypsine
treatment and co-cultured for 9 h at 37 1C with effector cells at the
ratio of 1:1 in DMEM supplemented with 10% FBS, rifampicin
(100 μg/ml) and cytosine arabinoside (100 nM). Subsequently,
cells were lysed and luciferase activity was measured using a
luminometer (Promega).
Viral complementation assay
To determine the effect of N-CHO site mutation on viral entry,
complementation assay was performed as previously described
with modiﬁcations (Connolly and Longnecker, 2012; Manoj et al.,
2004). In brief, BHK-21 cells growing in 6-well plates were
transfected with 4 mg plasmids expressing WT gB or mutants or
pcDNA3.1(þ) using Lipofectamine 2000 (Invitrogen). 24 h post-
transfection, cells were incubated with HSV-1 gB null virus (HSV-1
ΔgB Luc/GFP) for 2 h at 37 1C (MOI¼1). Virus inocula were
removed and the unpenetrated viruses were inactivated by expo-
sure of the cells to 0.1 mol/L citrate buffer (pH 3.0) for 1 min. After
three washes with PBS, cells were cultured in growth medium
(1 ml/well) for 24 h at 37 1C. To harvest the virus, BHK-21 cells
were lysed through three freeze-thaw cycles and cell debris was
removed by centrifugation. Subsequently, Vero and HeLa cells
growing in 96-well plates were infected with 50 μl/well of HSV-
1 gB null virus stock complemented with HSV-2 gBWT or mutants
for 24 h (Manoj et al., 2004). Cells were subsequently washed,
lysed and luciferase activity was detected. Virus entry was
assessed by quantifying the expression of luciferase.
Statistical analysis
Analyses were performed with GraphPad Prism 4.00 software
(GraphPad). Values were given as the mean of triplicates7stan-
dard deviation (SD) unless otherwise speciﬁed. Statistical analysis
was performed using the Student's t-test. A p valueo0.05 was
considered statistically signiﬁcant.
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